Handok (002390) - Total Assets
Based on the latest financial reports, Handok (002390) holds total assets worth ₩790.75 Billion KRW (≈ $535.88 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Handok debt service capacity to assess how comfortably operating cash covers total debt obligations.
Handok - Total Assets Trend (2011–2025)
This chart illustrates how Handok's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Handok for net asset value and shareholders' equity analysis.
Handok - Asset Composition Analysis
Current Asset Composition (December 2025)
Handok's total assets of ₩790.75 Billion consist of 40.4% current assets and 59.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 3.2% |
| Accounts Receivable | ₩157.06 Billion | 19.9% |
| Inventory | ₩94.39 Billion | 11.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩37.83 Billion | 4.8% |
| Goodwill | ₩44.50 Billion | 5.6% |
Asset Composition Trend (2011–2025)
This chart illustrates how Handok's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Handok.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Handok's current assets represent 40.4% of total assets in 2025, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 3.2% of total assets in 2025, up from 0.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 4.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 19.9% of total assets.
Handok Competitors by Total Assets
Key competitors of Handok based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.39 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Handok - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.77 | 0.96 | 1.42 |
| Quick Ratio | 0.54 | 0.67 | 0.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-95.41 Billion | ₩-13.44 Billion | ₩98.87 Billion |
Handok - Advanced Valuation Insights
This section examines the relationship between Handok's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.47 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.3% |
| Total Assets | ₩790.75 Billion |
| Market Capitalization | $78.88 Million USD |
Valuation Analysis
Below Book Valuation: The market values Handok's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Handok's assets grew by 0.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Handok (2011–2025)
The table below shows the annual total assets of Handok from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩790.75 Billion ≈ $535.88 Million |
+0.28% |
| 2024-12-31 | ₩788.56 Billion ≈ $534.39 Million |
-0.23% |
| 2023-12-31 | ₩790.34 Billion ≈ $535.60 Million |
-9.27% |
| 2022-12-31 | ₩871.11 Billion ≈ $590.34 Million |
+3.51% |
| 2021-12-31 | ₩841.56 Billion ≈ $570.31 Million |
+2.76% |
| 2020-12-31 | ₩818.93 Billion ≈ $554.97 Million |
+9.38% |
| 2019-12-31 | ₩748.67 Billion ≈ $507.36 Million |
+14.72% |
| 2018-12-31 | ₩652.62 Billion ≈ $442.27 Million |
+2.08% |
| 2017-12-31 | ₩639.35 Billion ≈ $433.28 Million |
+2.65% |
| 2016-12-31 | ₩622.85 Billion ≈ $422.10 Million |
+17.39% |
| 2015-12-31 | ₩530.59 Billion ≈ $359.57 Million |
+2.93% |
| 2014-12-31 | ₩515.49 Billion ≈ $349.34 Million |
+8.86% |
| 2013-12-31 | ₩473.53 Billion ≈ $320.90 Million |
+8.51% |
| 2012-12-31 | ₩436.39 Billion ≈ $295.74 Million |
+6.90% |
| 2011-12-31 | ₩408.21 Billion ≈ $276.64 Million |
-- |
About Handok
HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food sup… Read more